Hyperimmune immunoglobulin for people with COVID-19

Catherine Kimber, Sarah J. Valk, Khai Li Chai, Vanessa Piechotta, Claire Iannizzi, Ina Monsef, Erica M. Wood, Abigail A. Lamikanra, David J. Roberts, Zoe McQuilten, Cynthia So-Osman, Lise J. Estcourt, Nicole Skoetz*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

7 Citations (Scopus)


Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. Using a living systematic review approach, to assess whether hyperimmune immunoglobulin therapy is effective and safe in the treatment of people with COVID-19; and to maintain the currency of the evidence.

Original languageEnglish
Article numberCD015167
Number of pages26
JournalCochrane Database of Systematic Reviews
Issue number10
Publication statusPublished - 26 Jan 2023

Bibliographical note

Funding Information:
This project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No. 101015756. The contents of this document reflect only the authors' view and the Commission is not responsible for any use that may be made of the information it contains.

Funding Information:
The research was supported by NHS Blood and Transplant and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health.

Publisher Copyright:
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.


Dive into the research topics of 'Hyperimmune immunoglobulin for people with COVID-19'. Together they form a unique fingerprint.

Cite this